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Third-party Wharton’s jelly mesenchymal stem cells for treatment of steroid-resistant
acute and chronic graft-versus-host disease: a report of 10 cases
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Abstract: Severe graft-versus-host disease (GvHD) is a life-threatening complication after allogeneic hematopoietic stem cell
transplantation (HSCT). Bone marrow mesenchymal stem cells (BM-MSCs) display immunosuppressive activity and have been
previously shown to improve the outcome of GvHD therapy. We describe the use of umbilical cord mesenchymal stem cells (WJ-MSCs)
expanded in serum-free medium for the treatment of acute GvHD (aGvHD) and chronic GvHD (cGvHD) in 10 patients. After 1 to
3 WJ-MSC infusions at a median dose of 1.5 × 106 cells/kg recipient body weight, a complete or partial response was observed in 4/7
patients with aGvHD and in 2/3 patients with cGvHD. Five out of 6 patients (83.3%) from the responders group and only 1 out of 4
nonresponders (25%) survived the follow-up. The deaths occurred in patients with acute GvHD. In the responders group, 2 patients
showed complete remission of GvHD while symptoms of 4 patients were alleviated and the intensity of immunosuppressive therapy
could be reduced. No serious adverse effects were observed. In conclusion, WJ-MSCs appear to be safe and can be successfully applied
in the treatment of acute and chronic GvHD, but the therapeutic conditions should be optimized in prospective studies to maximize
their efficacy.
Key words: Umbilical cord, mesenchymal stem cells, hematopoietic stem cell transplantation, graft-versus-host disease, Wharton’s jelly

1. Introduction
Hematopoietic stem cell transplantations (HSCTs) can
be required as a consequence of marrow-ablative highdose chemotherapy in cases of several hematological and
neoplastic disorders. Hematopoietic stem cells for those
therapies are obtained usually from mobilized peripheral
blood, bone marrow, or umbilical cord blood (Tabbara
et al., 2002). Approximately 50% of patients receiving
HSCTs develop acute or chronic graft-versus-host disease
(aGvHD and cGvHD, respectively) (Pavletic et al., 2012).
The disease is caused by donor immunological cells that
recognize and attack host cells. Systemic inflammation
evoked by donor cells has a destructive effect on many
* Correspondence: katarzyna.pawelec@litewska.edu.pl

organs of the recipient, including the skin, gastrointestinal
tract, and liver (Blazar et al., 2012).
Mesenchymal stem cells (MSCs) are multipotent
stromal cells with unusual immunoregulatory features
(Le Blanc and Mougiakakos, 2012). They can be isolated
from various adult and neonatal tissues, with bone
marrow being the best-recognized source of MSCs, since
their first characterization by Pitenger et al. (1999). MSCs
are plastic adherent, have at least trilineage (osteoblasts,
chondroblasts, and adipocytes) differentiation capacity
in vitro, and show a characteristic surface antigen profile
(Horwitz et al., 2005; Dominici et al., 2006). Additionally,
MSCs are well recognized for their immunomodulatory
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plasticity, due to their ability to inhibit as well as increase
immune response (Wang et al., 2014).
Bone marrow mesenchymal stem cells (BM-MSCs)
have been shown to inhibit proliferation of both CD4+
and CD8+ T lymphocytes upon activation through
cellular or mitogenic stimuli (Di Nicola et al., 2002).
Furthermore, BM-MSCs inhibited proliferation of
lymphocytes stimulated by their cognate antigen and
decreased the number of IFN-γ expressing CD8+ T
cells (Krampera et al., 2013). The immunomodulatory
effect of BM-MSCs on lymphocytes is manifested also by
induction of differentiation of regulatory T cells, defined
as CD4+CD25+ FoxP3+ or CTLA4+ from CD4+ T helper
cells upon co-culture with BM-MSCs (Maccario et al.,
2005; English et al., 2009). However, what is important
from the clinical point of view is that BM-MSCs do not
suppress virus-induced cytotoxic T cell proliferation or
IFN-γ production, and therefore upon infusion will not
compromise T cell mediated virus immunity (Karlsson
et al., 2008). Those immunomodulatory properties are
exerted through soluble factors such as transforming
growth factor β (TGF-β), hepatocyte growth factor (HGF)
(Di Nicola et al., 2012), and prostaglandin E2 as well as
through direct cell-to-cell contact (English et al., 2009).
Due to their immunosuppressive activity, BM-MSCs
have already been applied in experimental therapies
and clinical studies for the treatment of GvHD. The first
successful application of BM-MSCs was described by Le
Blanc et al. (2004) in a boy with steroid-resistant grade
IV aGvHD and resulted in complete remission. Another
study showed successful treatment of aGvHD with 0.7–9
× 106 BM-MSCs per kg body weight in six out of eight
patients (Ringdén et al., 2006). A large phase II study
on the use of BM-MSCs in steroid-resistant aGvHD in
both children and adults was conducted by Le Blanc
et al. (2008). In total, 55 patients were treated with a
median dose of 1.4 × 106 BM-MSCs per kg body weight.
Approximately half of the patients received two or more
cell infusions. Most of the cells used in the study were
derived from HLA-mismatched third-party donors.
Complete or partial treatment response was observed in
70% of the patients regardless of HLA identity. No toxic
effects after cell infusions were noted. Another study
(Kebriaei et al., 2009) used BM-MSCs in combination with
steroids and confirmed high response rates: complete in
77% and partial in 16% of patients. The study administered
two different MSC doses (2 or 8 × 106 per kg body weight),
but the investigators did not notice any influence of the cell
dose on the efficacy of stem cell therapy.
In contrast to aGvHD, data about the use of BMMSCs for cGvHD therapy are limited. Intrabone marrow
infusion of BM-MSCs was used to treat cGvHD after
nonmyeloablative HSCT in 4 patients (Zhou et al., 2010).
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BM-MSC infusions ameliorated clinical symptoms and
all patients were alive after a follow-up period of 4–23
months. In another study (Weng et al., 2010), conducted
in 19 patients, 14 achieved complete or partial treatment
response within the median follow-up of 697 days.
Fourteen patients survived the therapy and ten of them
were able to taper or discontinue immunosuppressive
therapy.
MSCs can be also isolated from Wharton’s jelly, which
is located within the umbilical cord. These umbilical cord
mesenchymal stem cells (WJ-MSCs) are plastic adherent
and are capable of multilineage differentiation. Similar to
BM-MSCs, WJ-MSCs express characteristic mesenchymal
surface antigens such as CD29, CD90, and CD105
although lacking the hematopoietic antigen CD34 (Secco
et al., 2008; Troyer and Weiss et al., 2008). However, WJMSCs are more easily isolated as the umbilical cord can
be collected without any additional medical procedures.
The quantity of mesenchymal cells in the umbilical cord
is higher than that in the bone marrow. In addition, WJMSCs have shorter doubling times, proliferate more
efficiently, and can be cultured in vitro longer than BMMSCs (Lu et al., 2006). Furthermore, WJ-MSCs display
immunomodulatory properties greater than BM-MSCs.
WJ-MSCs have been shown to inhibit proliferation
of stimulated splenocytes and lymphocytes as well as
expressing IL-6, which is associated with MSC-induced
immunosuppression. What is important is that WJ-MSCs
did not elicit lymphocyte proliferation and expressed low
levels of co-stimulatory molecules (Weiss et al., 2008). In
addition, WJ-MSCs inhibited production of IFN-γ and
TNF-α by stimulated T cells (Yoo et al., 2009). Finally,
WJ-MSCs decreased maturation of monocyte-derived
dendritic cells (DCs) and inhibited the endocytic activity
of DCs (Saeidi et al., 2013). Wu et al. (2011) described
the use of WJ-MSCs for the treatment of aGvHD in 2
children. After 4 infusions of WJ-MSCs both patients
showed complete treatment response and discontinued
immunosuppressive therapy. This was probably the first
clinical WJ-MSC application.
We would like to describe the results of a clinical
study on the use of WJ-MSCs for the treatment of 10
patients with steroid-resistant GvHD including 7 patients
diagnosed with aGvHD and 3 patients with cGvHD.
2. Materials and methods
2.1. Sampling and cell culture
All umbilical cord (UC) samples were obtained after
patients provided informed consent. Ethical approval
was given by the Bioethical Committee. UC samples
were collected after natural delivery as well as cesarean
sections. Transport conditions were monitored and tissue
was processed within 48 h of delivery. UC fragments were
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washed in a sterile saline with Antibiotic Antimycotic
solution (Gibco, USA). They were dissected and blood
vessels were removed. Wharton’s jelly was minced into
2-cm3 scraps with a sterile lancet and placed into 6-well
plates covered with MSC Attachment solution (Biological
Industries, Israel) according to the manufacturer’s
recommendations and grown in serum-free medium for
human mesenchymal stem cells NutriStem XF (Biological
Industries, Israel) with NutriStem XF Supplement
Mix (Biological Industries, Israel) with the addition of
Antibiotic-Antimycotic solution (Gibco, Poland). The
culture was incubated at 37 °C in 5% CO2 in the air. The
nonadherent cells were washed off and the attached cells
were expanded further. Tissue explants were removed after
2–3 weeks of culture. Adherent cells were passaged upon
reaching 90% confluence and reseeded at 1.2 × 104 cells/
cm2 in 75-cm2 tissue culture flasks (BD, USA) for further
culture expansion. After trypsinization with trypsin
solution (Biological Industries, Israel) the number of cells
was evaluated in a hemocytometer. When the required
number of cells was obtained, they were transferred to a
freezing bag and resuspended in human albumin (CSL
Behring, USA) in the presence of 10% DMSO (WAKChemie, Germany), cooled with controlled rate freezer
(Sy-Lab IceCube 14S, Austria), and then placed in the
vapor phase of liquid nitrogen. Viability was determined
on the basis of the thawed reference sample and counted
by trypan blue exclusion in the hemocytometer. The
viability of cells used for transplantation was between 95%
and 97%.
2.2. Immunophenotyping of human umbilical cord
MSCs
Characterization of human umbilical cord derived MSCs
was carried out in accordance with the minimal criteria
of MSCs described elsewhere (Dominici et al., 2006) by
immunophenotyping using both MSC-positive and MSCnegative surface markers. Briefly, 60% to 80% confluent
flasks of expanded MSCs were trypsinized and then
incubated with following antibodies in darkness for 30
min. Cells were stained with antibodies against CD34
FITC, CD14 FITC, CD19 FITC, CD45 FITC, and HLADR FITC as a negative surface markers; CD73 PE, CD90
PE, CD105 PE, and HLA-ABC FITC as positive surface
markers; and mouse IgG1 FITC with mouse IgG1 PE as
controls. Then cells were washed with a cell wash solution
(BD, USA), resuspended in Cell Fix solution (BD, USA),
and finally analyzed using a FACS CALIBUR (BD, USA)
flow cytometer. Flow cytometry analysis confirmed the
mesenchymal phenotype of the cells.
3. Results
The study group varied in terms of age, number of
infusions, previous treatment applied, the dose of cells,

and type of GvHD. Furthermore, the study was performed
in 10 patients only; therefore, general analysis of clinical
outcomes and statistical assessment were not feasible.
Instead, clinical results will be presented as a case study.
3.1. Case series
3.1.1. aGvHD patients
Case 2. A 20-year-old woman, diagnosed with ALL, was
subjected to bone marrow transplantation obtained from
an HLA-fully matched unrelated donor. HSCT resulted in
complete remission with positive minimal residual disease.
However, the woman developed severe, grade IV aGvHD.
The symptoms affected the gastrointestinal tract, liver, and
skin. The patient received extended immunosuppressive
treatment including etanercept (ETN), antithymocyte
globulin, methotrexate, and monoclonal antibody
treatment. Despite multiple treatment regimes, her
bilirubin level reached critical levels of over 20 mg/dL.
Therefore, 51 days after the GvHD diagnosis, the patient
received WJ-MSCs at a dose of 1.1 × 106 cells per kg body
weight. Cell infusion was repeated 7 days later at the same
dose. Unfortunately, patient died 25 days after the second
infusion due to hepatic encephalopathy.
Case 3. A 7-year-old girl was admitted to hospital
due to ALL in second remission. She was subjected to
BM-HSCT from an HLA-matched unrelated donor and
developed grade IV aGvHD 19 days after the HSCT. The
symptoms were restricted to the gastrointestinal tract, with
stool volume over 4000 mL per day and presence of blood.
Additional pharmacological treatment, which consisted
of tacrolimus (FK506), intravenous immunoglobulin
(IVIG), monoclonal antibodies, and ETN, was applied.
Furthermore, the patient received a third party WJ-MSC
infusion at a dose of 1.7 × 106 cells per kg body weight 22
days after the diagnosis of aGvHD. After cell infusion the
girl was subjected to multiple extracorporeal photopheresis
(ECP) procedures. The combined treatment resulted in
remission of GvHD. Approximately 4 months after the
diagnosis, the patient was discharged from hospital in
good general condition, without symptoms of GvHD.
Case 4. The fourth case of WJ-MSC application was
in a 5-year-old boy, who suffered from AML. The patient
received two subsequent HSCTs from BM and mobilized
peripheral blood. He developed grade IV aGvHD that
affected his skin, gastrointestinal tract, and liver and
resulted in microangiopathy. In addition to the standard
therapy, he received the second-line pharmaceutical
treatment with ETN. Furthermore, the boy was subjected to
6 ECP procedures. No clinical improvement was achieved;
therefore, WJ-MSCs from a third-party donor were applied
36 days after the GvHD diagnosis. Two subsequent cell
infusions were performed, with a total cell dose of 2.6 ×
106 cells per kg body weight. Partial clinical improvement
was obtained in terms of reduced stool volume and
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disappearance of the obstruction. Unfortunately, the boy
died 3 months after stem cell treatment due to bleeding to
the central nervous system and sudden cardiac arrest.
Case 5. An 18-year-old man with ALCL in second
complete remission was treated with HSCT from a
9/10 HLA-matched related donor. The HSCT caused
development of grade IV aGvHD. The symptoms affected
the gastrointestinal tract, skin, and liver. Despite extended
treatment with ETN, ECP, anti-thymocyte globulin (ATG),
and monoclonal antibodies, the clinical state of the patient
did not improve. Therefore, 26 days after the diagnosis of
GvHD, WJ-MSC infusion was performed. The cells were
infused at a dose of 2.4 × 106 cells per kg body weight. He
received two MSC doses; however, the GvHD symptoms
were not alleviated after cell infusions. The patient died 4
months after cell application due to sepsis.
Case 6. A 3-year-old girl suffering from AML
underwent a bone marrow transplantation from an
unrelated, HLA-matched donor. After HSCT the patient
was diagnosed with grade III acute GvHD that affected
the gastrointestinal tract. Application of steroids did not
result in clinical improvement. Additional treatment with
ATG and monoclonal antibodies was applied. Despite
therapy, GvHD symptoms persisted. Therefore, WJ-MSCs
were applied in 3 subsequent infusions at a total dose of
4.9 × 106 cells per kg body weight. The first infusion was
conducted 28 days after the diagnosis. As a result of cell
therapy, a reduction in stool volume was noted and the
patient could be fed orally.
Case 7. A 3½-year-old boy underwent HSCT from
mobilized peripheral blood, from an unrelated, HLAmatched donor, due to ALL in second remission. After
transplantation the patient was diagnosed with grade IV
aGvHD. The symptoms were widespread, affecting the
gastrointestinal tract, skin, liver, and bone marrow. In

addition to steroids, the patient received ETN, ATG, IVIG,
and monoclonal antibodies but the pharmacological
treatment did not lead to any improvement. MSCs were
applied 38 days after the diagnosis in the form of one
WJ-MSC infusion, using a dose of 1.6 × 106 cells per kg
body weight. The cell infusion did not result in any clinical
improvement. The patient died 17 days after the infusion
due to GvHD progression and sepsis.
Case 8. A 3-year-old boy underwent transplantion
due to AML transformed from MDS. The patient received
HSCT from an HLA-matched, unrelated donor, which
caused development of grade IV aGvHD. The disease
was manifested in the gastrointestinal tract and skin. In
addition to standard immunosuppressive treatment, ETN,
ATG, and MoAB were applied. Furthermore, the patient
was subjected to ECP. Due to lack of clinical improvement,
he received one WJ-MSC infusion at a dose of 1.5 × 106
cells per kg body weight. After cell infusion, remission of
the gastrointestinal tract symptoms occurred, but the skin
symptoms were not significantly affected. Eventually, the
symptoms were completely alleviated and the patient was
discharged from hospital without GvHD manifestations.
For a summary of the aGvHD patients, please see Table 1.
3.1.2. cGvHD patients
Case 1. A 16-year-old patient suffering from MDS was
given an HSCT from an unrelated donor. Despite preventive immunosuppressive treatment the patient showed an
exacerbation of extensive cGvHD. The disease symptoms
affected the skin, gastrointestinal tract, liver, mucosa, and
bone marrow. Furthermore, the patient suffered from
microangiopathy and dry eye syndrome. In addition to
general immunosuppressive treatment she also received
ETN and IVIG and was subjected to ECP. However, the
treatment did not bring about a significant improvement.
Therefore, 186 days after the diagnosis the patient received

Table 1. Treatment of acute GvHD with WJ-MSCs.
Case no.

GvHD

Treatment before MSCs

Time from diagnosis

Clinical outcome

Follow-up

2

Grade IV: S, GI, L

GCs, CsA, MMF, ETN, MoAB

51 days

NR

Death

3

Grade IV: GI

GCs, CsA, MMF, FK506, ETN, MoAB, IVIG, ECP

22 days

CR

Alive

4

Grade IV: S, GI, L, microangiopathy

GCs, CsA, MMF, ETN, IVIG, ECP

36 days

PR

Death

5

Grade IV: S, GI, L

GCs, CsA, MMF, ETN, ATG, MoAB, IVIG, ECP

26 days

NR

Death

6

Grade III: GI

GCs, CsA, MMF, ATG, MoAB

28 days

PR

Alive

7

Grade IV: S, GI, L, bone marrow

GCs, MMF, ETN, ATG, MoAB, IVIG

38 days

NR

Death

8

Grade IV: S, GI

GCs, CsA, MMF, ETN, ATG, MoAB, IVIG, ECP

24 days

CR

Alive

Abbreviations: GvHD – Graft-versus-host disease, S – skin, GI – gastrointestinal tract, L – liver, MSCs – mesenchymal stem cells, GCs – glucocorticoids, CsA – cyclosporine
A, MMF – mycophenolate mofetil, ETN – entanercept, MoAB – monoclonal antibodies, FK508 – tacrolimus, IVIG – intravenous immunoglobulins, ECP – extracorporeal
photopheresis, NR – no response, CR – complete response, PR – partial response.
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2 WJ-MSC infusions with a total dose of 1.8 × 106 cells per
kg body weight. The infusion was repeated 1 week after the
first procedure. The cell injections resulted in complete remission of gastrointestinal tract symptoms and alleviation
of symptoms affecting other organs. At the end of the follow-up period, the condition of the patient was classified
as limited cGvHD. Immunosuppressive treatment could
be reduced and the patient was discharged from hospital.
Case 9. The patient was an 18-year-old male who underwent HSCT due to SAA. The transplantation was repeated because of primary graft failure. After the second
HSCT the patient was diagnosed with extensive cGvHD
with symptoms manifested mainly in the skin. He was
treated with standard immunosuppressive agents, GCs,
CsA, and MMF. However, during long-term treatment
his condition did not improve. Therefore, the patient was
qualified for WJ-MSC administration. Nearly 2 years after
the onset of cGvHD, he received 1 infusion with a dose of
1.1 × 106 cells per kg body weight. Three months from the
infusion, the intensity of symptoms decreased significantly
and the dose of immunosuppressants could be reduced.
The patient was alive at the end of the follow-up period
and suffered from limited cGvHD.
Case 10. A 17-year-old male was given HSCT due to
AML in second remission. The transplantation caused the
development of extensive cGvHD. The symptoms were restricted to the skin, which was affected by diffuse scleroderma. Prolonged immunosuppressive treatment with
GCs, CsA, and MMF did not lead to clinical improvement.
Therefore, 454 days after the diagnosis of cGvHD, the patient received a single injection of WJ-MSCs at a dose of
1.5 × 106 cells per kg of body weight. The cell injection did
not lead to alleviation of cGvHD symptoms. Immunosuppressive treatment had to be continued. At the end of the
follow-up period, the patient was alive and still suffering
from extensive cGvHD.
For a summary of the cGvHD patients, please see Table 2.
3.2. Conclusions
MSC therapy was applied to 10 patients who were first
diagnosed with myelodysplastic syndrome (MDS), acute
lymphoblastic leukemia (ALL), acute myeloid leukemia

(AML), severe aplastic anemia (SAA), or anaplastic largecell lymphoma (ALCL). All of them underwent HSCT
as a treatment for the primary disorder. After HSCT, despite prophylactic immunosuppressive treatment (CsA,
MMF), patients developed GvHD. The group consisted
of 7 aGvHD and 3 cGvHD cases. The age of the patients
ranged from 3 to 20 years (median age of 11.5 years).
GvHD symptoms were not alleviated despite GCs, CsA,
and MMF treatment. A number of patients were given additional treatment, such as anti-TNF therapy (e.g., etanercept), monoclonal antibody treatment, and extracorporeal
photopheresis (ECP). The only enrollment criterion was
the lack of clinical improvement after standard therapy.
MSC infusion was considered as a salvage therapy. Each
patient received 1–3 infusions of third party WJ-MSCs. In
the aGvHD group, the patients received the first dose 22–
51 days (median of 28 days) after the diagnosis of GvHD.
Patients suffering from cGvHD were treated with cells
186–625 days (median of 454 days) after the diagnosis.
Cells were injected intravenously at a median dose of 1.5 ×
106 cells per kg body weight (from 1.1 to 4.9 × 106 cells/kg).
A positive treatment response was observed in 6 out
of 10 patients. In the group of positive responders, 2 patients suffering from aGvHD showed complete remission
of symptoms with no signs of GvHD during follow-up.
Four patients displayed amelioration of GvHD symptoms.
This group consisted of 2 patients with cGvHD and 2 patients with aGvHD. One of the patients with aGvHD, who
showed initial improvement, died after 3 months from cell
infusion due to central nervous system bleeding. Four patients out of 10 enrolled in the study did not respond to cell
infusions. One patient died within 4 months of the cell infusion due to progression of aGvHD symptoms. The condition of 1 patient suffering from cGvHD did not improve,
but he stayed alive throughout the follow-up period. The
survival rate at 1 year follow-up was 83.3% (5/6) for patients who responded to the therapy (complete remission
or partial response) and only 25% (1/4) for nonresponders.
None of the patients showed any immediate or longterm toxic effects directly related to cell therapy. Only one
patient had mild tachycardia, which did not need pharma-

Table 2. Treatment of chronic GvHD with WJ-MSCs.
Case no.

GvHD

Treatment before MSCs

Time from diagnosis

Clinical outcome

Follow-up

1

Extensive: S, GI, L, mucosa, bone marrow,
microangiopathy, dry eye syndrome

GCs, CsA, MMF, ETN, IVIG, ECP

186 days

PR

Alive, currently
treated with ECP

9

Extensive: S

GCs, CsA, MMF

625 days

PR

Alive

10

Extensive: S, with diffuse scleroderma

GCs, CsA, MMF

454 days

NR

Alive

Abbreviations: GvHD – Graft-versus-host disease, S – skin, GI – gastrointestinal tract, L – liver, MSCs – mesenchymal stem cells, GCs – glucocorticoids, CsA – cyclosporine
A, MMF – mycophenolate mofetil, ETN – entanercept, IVIG – intravenous immunoglobulins, ECP – extracorporeal photopheresis, PR – partial response, NR – no response.
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cologic treatment. As a result of the multiple therapeutic
approaches applied, one of the patients showed an adverse
side effect, which was stable, mild tachycardia.
4. Discussion
A number of studies describing the use of BM-MSCs for the
treatment of aGvHD have been performed; see an excellent
review by Amorin et al. (2014). However, very limited data
on the use of WJ-MSCs exist. WJ-MSCs were successfully
expanded in a chemically defined, serum-free medium,
which makes the cell preparation protocol suitable for
routine clinical application. We have observed positive
effects of cell application in both aGvHD and cGvHD
patients including 2 patients with complete remission of
disease symptoms. Moreover, MSC therapy appears safe as
none of the patients developed adverse effects. The study
was performed in 10 patients only; therefore, detailed
analysis of therapy outcome with relation to number of
infusions, time from diagnosis to application, cell dose,
type of GvHD, and age of patient could not be peformed.
WJ-MSC infusions were performed in severe GvHD cases
where pharmacological treatment did not lead to clinical
improvements.
Application of WJ-MSCs was also described by Wu et
al. (2011) in 2 children with aGvHD. The patients received
2 or 3 infusions of cells before the symptoms disappeared.
In this paper, the authors provide further data of seven
aGvHD cases treated with WJ-MSCs. The patients
received from 1 to 3 infusions, yet the therapy outcome
did not correlate with the number of infusions. However, it
is worth noting that 2 cases of complete disease remission
were observed in patients who received only 1 infusion.
Furthermore, those patients received cell infusions 22 and
24 days after the GvHD diagnosis, which were the earliest
cell applications in the aGvHD group. This result suggests
that timing rather than number of infusions is crucial for
therapy outcomes. Early infusion of BM-MSCs has been
shown to increase the frequency of complete remission
cases in children, which reached 78% compared to 52% in
late infusion cases (Ball et al., 2013). The same relationship
probably exists for WJ-MSCs, but the hypothesis has to be
verified experimentally.
We also provide data on the treatment of severe cGvHD
with WJ-MSCs, which has not been described previously.
Two out of 3 patients partially responded to cell infusion
and alleviation of symptoms was observed. A different study
described the results of BM-MSC infusion for treatment of
cGvHD, where 4 patients showed improvement, but some
symptoms persisted (Zhou et al., 2010). The outcomes of
a study performed on a larger group of cGvHD patients
were similar. Out of 19 patients treated, 10 showed partial
response and complete remission was observed in 4 cases
(Weng et al., 2010). Therefore, the first cases of cGvHD

498

treatment with WJ-MSCs are in agreement with previous
studies utilizing BM-MSCs and indicate that WJ-MSCs
can successfully treat cGvHD. Partial response of patients
with cGvHD to WJ-MSC infusion might originate from
the mechanism of MSCs’ immunosuppressive activity. It
has been demonstrated that BM-MSCs inhibit T cells and
B cells upon exposure to IFN-γ (Krampera et al., 2003).
The immunosuppressive functions of WJ-MSCs are also
markedly more efficient in the presence of IFN-γ (Prasanna
et al., 2010). As aGvHD is accompanied by high levels of
IFN-γ, MSCs are primed towards immunosuppression
after infusion. However, in cGvHD IFN-γ levels are lower
(Blazar et al., 2012) and, as a consequence, suppression
of T cell proliferation and activation by MSCs might be
less efficient. Therefore, in future applications of MSCs
for cGvHD, a transient exposure of cells to IFN-γ before
infusion might provide additional stimulation of cells’
immunosuppressive activity and thus improve therapy
outcome. In an alternative approach, MSCs have been
co-infused with hematopoietic stem cells to enhance
engraftment and prevent GvHD. SAA has been treated
with both BM-MSCs and WJ-MSCs co-infused during
allogeneic HSCT. The co-infusions resulted in low risk
of severe GvHD occurrence, efficient engraftment, and
allowed a decrease in the intensity of immunosuppressive
conditioning. However, the studies did not include a
control group of patients who received HSCT without
MSCs; therefore, lower incidence of GvHD cannot be
unambiguously linked with WJ-MSC co-infusion (Li XH et
al., 2014; Li ZY et al., 2014; Wu et al., 2014). Data gathered
in preclinical studies on mice suggest that umbilical cord
blood (UCB) and BM-MSC co-transplantation after bone
marrow ablation resulted in reduced severity of GvHD
compared to the control group that received only UCB (Li
ZY et al., 2014). However, co-infusion of adipose tissuederived MSCs and UCB in a model of relapsed chronic
myeloid leukemia did not result in decreased frequency
of GvHD occurrence (Oviedo et al., 2013). Therefore,
administration of MSCs together with hematopoietic
transplantation might not prevent GvHD if leukemic cells
are present in circulation.
In conclusion, WJ-MSCs can be effectively isolated
and expanded in a serum-free medium. Infusion of WJMSCs was safe and provided clinical improvement in
several patients when applied as a salvage therapy for
acute and chronic GvHD. WJ-MSC therapy for GvHD
has to be further optimized in prospective studies. Based
on our own experience and previous studies, in order to
maximize therapeutic efficacy, we suggest that cells should
be administrated early after GvHD diagnosis and multiple
infusions could be conducted if initial improvement is not
observed.
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